Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$19429.5.

  • Ascendis Pharma A's EPS (Basic) fell 21614.85% to -$19429.5 in Q3 2025 from the same period last year, while for Sep 2025 it was -$19429.5, marking a year-over-year decrease of 21614.85%. This contributed to the annual value of -$6.53 for FY2024, which is 2407.65% up from last year.
  • Per Ascendis Pharma A's latest filing, its EPS (Basic) stood at -$19429.5 for Q3 2025, which was down 21614.85% from $18132.4 recorded in Q2 2025.
  • Ascendis Pharma A's EPS (Basic)'s 5-year high stood at $56971.7 during Q1 2024, with a 5-year trough of -$59937.3 in Q1 2025.
  • Moreover, its 5-year median value for EPS (Basic) was -$1.94 (2021), whereas its average is -$6162.7.
  • Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 23261.31% in 2023, then skyrocketed by 20098.75% in 2024.
  • Ascendis Pharma A's EPS (Basic) (Quarter) stood at -$1.94 in 2021, then tumbled by 91.03% to -$3.7 in 2022, then surged by 57.56% to -$1.57 in 2023, then surged by 57.68% to -$0.66 in 2024, then crashed by 2923824.3% to -$19429.5 in 2025.
  • Its EPS (Basic) stands at -$19429.5 for Q3 2025, versus $18132.4 for Q2 2025 and -$59937.3 for Q1 2025.